Article Details
Retrieved on: 2024-11-05 16:11:19
Tags for this article:
Click the tags to see associated articles and topics
Summary
Beam Therapeutics' BEAM-101 shows promising early results in treating sickle cell disease by inducing fetal hemoglobin, amid concerns over current conditioning treatments. This advance in gene therapy is especially relevant for healthcare challenges in Africa.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here